Astellas Announces FDA Update on the FORTIS Clinical Trial o

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the US Food and Drug Administration (FDA)...

Related Keywords

San Francisco , California , United States , China , Tokyo , Japan , Netherlands , South San Francisco , Israel , Chinese , Kenji Yasukawa , Weston Miller , Drug Administration , Israel Journal Of Medical Sciences , Clinical Development At Astellas , Pediatric Research , Astellas Pharma Inc , Astellas Center , Fortis , American College Of Medical Genetics , Astellas Pharma , Late Onset Pompe , Senior Medical Director , Clinical Development , Late Onset Pompe Disease , Focus Area Approach , Gene Therapies , American College , Medical Genetics , Human Genetics , Inherited Metabolic Disease , Israel Journal , Medical Sciences , Lysosomal Storage ,